

Mochida announces Termination of License Agreement with Wyeth

(Tokyo, April 13, 2010) – Mochida Pharmaceutical announces that the License Agreement with Wyeth LLC (acquired by Pfizer as of October 2009) relating to a potential novel treatment for pain has terminated. Under an exclusive license to develop, manufacture, use and sell pharmaceutical products containing TRPV1 receptor antagonists invented by Mochida, Wyeth Pharmaceuticals had conducted the research and development relating to these TRPV1 antagonists.

Upon the termination of the License Agreement, Mochida gets back the exclusive right relating to these TRPV1 antagonists. Mochida is expecting to develop them under a new framework.